인벤티지랩
Financials
Valuation Metrics
인벤티지랩's Market Cap is ₩3028B. At end of 2025 it was ₩1.1T. Ranked #610 of 2,410 in KR market (top 25%), #249 of 1,631 on KOSDAQ (top 15%), #64 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 302.75B KRW | KR#610/2,410 Sec#64/231 |
| Revenue | 2.47B KRW | KR#2,367/2,410 Sec#210/231 |
| Net Income | -10.77B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 194.14B KRW | KR#1,336/2,410 Sec#97/231 |
| Net Assets | 111.08B KRW | KR#1,337/2,410 Sec#105/231 |
| Employees | 69 | KR#1,883/2,410 Sec#163/231 |
| Value | ||
| P/B | 2.73x | KR#2,102/2,410 Sec#164/231 |
| P/S | 122.43x | KR#2,385/2,410 Sec#213/231 |
| FCF Yield | -8.55% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -9.69% | KR#1,926/2,410 Sec#145/231 |
| ROA | -5.55% | KR#1,954/2,410 Sec#142/231 |
| Op. Margin | -1359.73% | KR#2,371/2,410 Sec#216/231 |
| Revenue Growth | 6.06% | KR#1,128/2,410 Sec#112/231 |
| Financial Health | ||
| Debt Ratio | 74.77% | KR#1,273/2,410 Sec#152/231 |
| Total Debt | 28.93B KRW | KR#1,244/2,410 Sec#97/231 |
| FCF | -25.89B KRW | KR#1,947/2,410 Sec#188/231 |
| Cash | 97.59B KRW | KR#478/2,410 Sec#24/231 |
| Current Ratio | 2.86x | KR#591/2,410 Sec#79/231 |
| Performance | ||
| 1Y Return | -55.39% | KR#2,053/2,410 Sec#185/231 |
| 1M Return | -19.61% | KR#1,656/2,410 Sec#164/231 |
| From 52W High | -77.63% | KR#2,261/2,410 Sec#203/231 |
| 1Y MDD | -77.79% | KR#2,237/2,410 Sec#196/231 |
| Trading | ||
| Volume | 47,091 shares | KR#1,146/2,410 Sec#116/231 |
| Trading Value | 1.08B KRW | KR#631/2,410 Sec#65/231 |
| Foreign Own. | 10.99% | KR#441/2,410 Sec#35/231 |
| Per Share | ||
| EPS | -809 KRW | KR—/2,410 Sec—/231 |
| BPS | 8,347 KRW | KR#1,116/2,410 Sec#80/231 |
Company Info
Inventis Lab was established in 2015, and in 2025, it acquired KOSDAQ-listed Curatis, securing a mass production base for long-acting injectable drugs and gene therapy/mRNA vaccines. It possesses an IVL platform that applies microfluidic technology to drug research and development, providing long-acting injectable drug development and LNP manufacturing services. The company has license agreements with domestic and international pharmaceutical companies and is expanding clinical trial material production and CDMO business through manufacturing facilities in Curatis' GMP factory. Inventis Lab is headquartered in Seongnam-si, Gyeonggi-do.